These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Landy SH, Tepper SJ, Wein T, Schweizer E, Ramos E. Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799 [Abstract] [Full Text] [Related]
9. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Arch Fam Med; 1998 Jan; 7(3):234-40. PubMed ID: 9596457 [Abstract] [Full Text] [Related]
11. Cluster Headache Clinical Phenotypes: Tobacco Nonexposed (Never Smoker and No Parental Secondary Smoke Exposure as a Child) versus Tobacco-Exposed: Results from the United States Cluster Headache Survey. Rozen TD. Headache; 2018 May; 58(5):688-699. PubMed ID: 29536529 [Abstract] [Full Text] [Related]
12. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. van Vliet JA, Bahra A, Martin V, Ramadan N, Aurora SK, Mathew NT, Ferrari MD, Goadsby PJ. Neurology; 2003 Feb 25; 60(4):630-3. PubMed ID: 12601104 [Abstract] [Full Text] [Related]
13. Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group. Ekbom K, Krabbe A, Micieli G, Prusinski A, Cole JA, Pilgrim AJ, Noronha D, Micelli G [corrected to Micieli G]. Cephalalgia; 1995 Jun 25; 15(3):230-6. PubMed ID: 7553814 [Abstract] [Full Text] [Related]
16. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. J Psychoactive Drugs; 2015 Jun 25; 47(5):372-81. PubMed ID: 26595349 [Abstract] [Full Text] [Related]